ロード中...
Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
BACKGROUND: PARP inhibitors, such as Olaparib, have advanced the treatment of ovarian cancer by providing patients with an effective and molecularly-targeted maintenance therapy. However, all orally-administered drugs, including Olaparib, must undergo first-pass metabolism. In contrast, a nanopartic...
保存先:
| 出版年: | Int J Nanomedicine |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278886/ https://ncbi.nlm.nih.gov/pubmed/30555227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S186881 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|